MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.19.01892

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Frey Noelle V, Shaw Pamela A, Hexner Elizabeth O, Pequignot Edward, Gill Saar, Luger Selina M, Mangan James K, Loren Alison W, Perl Alexander E, Maude Shannon L, Grupp Stephan A, Shah Nirav N, Gilmore Joan, Lacey Simon F, Melenhorst Jos J, Levine Bruce L, June Carl H, Porter David L

Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential in adults. We report outcomes for adults with r/r ALL treated with an optimized CTL019 dosing and CRS management strategy.

METHODS

Adults with r/r B-cell ALL received CTL019 in 1 of 2 trials. Patients received lymphodepletion followed by CTL019 as either a one-time infusion or fractionated infusions split over 3 days (day 1, 10%; day 2, 30%; day 3, 60%), which allowed for day 2 and day 3 doses to be held for early CRS. Total planned CTL019 dose varied with adaptive protocol modifications in response to efficacy and CRS toxicity.

RESULTS

Thirty-five adults with r/r ALL received CTL019 in 1 of 3 dosing cohorts. The low-dose cohort (n = 9) received single or fractionated dosing and had manageable toxicity with a 33% complete remission (CR) rate. In the high-dose single infusion cohort, 3 of 6 patients with refractory CRS concurrent with culture-positive sepsis died, and 3 achieved CR. The 20 patients in the high-dose fractionated (HDF) cohort had a 90% CR rate and manageable CRS. The HDF cohort had the highest survival, with a 2-year overall survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%).

CONCLUSION

Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL.

Для цитирования: Frey Noelle V, Shaw Pamela A, Hexner Elizabeth O, Pequignot Edward, Gill Saar, Luger Selina M, Mangan James K, Loren Alison W, Perl Alexander E, Maude Shannon L, Grupp Stephan A, Shah Nirav N, Gilmore Joan, Lacey Simon F, Melenhorst Jos J, Levine Bruce L, June Carl H, Porter David L. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019. DOI: 10.1200/jco.19.01892.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.